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Abstract   
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with 
local immunoglobulin hyperproduction and the presence of IgE antibodies against 
Staphylococcus aureus enterotoxins (SAEs). Aspirin-exacerbated respiratory 
disease (AERD) is a severe form of CRSwNP in which nearly all patients express 
anti-SAEs. 
 
Objectives: We aimed to understand antibodies reactive to SAEs and determine 
whether they recognize SAEs through their complementarity-determining regions 
(CDRs) or framework regions (FRs). 
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Methods: Labeled Staphylococcal enterotoxin A (SEA), SED and SEE were used to 
isolate single SAE-specific B cells from the nasal polyps of three AERD patients by 
FACS. Recombinant antibodies with “matched” heavy- and light-chains were cloned 
as IgG1, and those of high-affinity for specific SAEs, assayed by ELISA and surface 
plasmon resonance (SPR), were re-cloned as IgE and Fab. The activities of the IgEs 
were tested in basophil degranulation assays. 
 
Results: Thirty-seven SAE-specific, IgG or IgA-expressing B cells were isolated and 
yielded six anti-SAE clones, two each for SEA, SED and SEE. Competition binding 
assays revealed that the anti-SEE antibodies recognize non-overlapping epitopes in 
SEE. Unexpectedly, each anti-SEE mediated SEE-induced basophil degranulation and 
IgG1 or Fab of each anti-SEE enhanced degranulation by the other anti-SEE.  
 
Conclusions: SEE may activate basophils by simultaneously binding as antigens in 
the conventional manner to CDRs and as superantigens to FRs of anti-SEE IgE in 
anti-SEE IgE-FcεRI complexes. Anti-SEE IgG1s may enhance the activity of anti-SEE 
IgEs as conventional antibodies via CDRs or simultaneously as conventional 
antibodies and as “superantibodies” via CDRs and FRs to SEEs in SEE-anti-SEE IgE-
FcεRI complexes (Figure 7).  
 
Clinical Implications 
Anti-SAE IgE antibodies alone or together with IgG1 may contribute to the 
pathogenesis of CRSwNP and allergic disease.  
 
Capsule Summary 
Both IgG and IgE antibodies against SAEs may have pro-inflammatory activity in 
CRSwNP 
 
Key words 
Chronic rhinosinusitis with nasal polyps (CRSwNP), Aspirin-exacerbated 
respiratory disease (AERD), Staphylococcus aureus enterotoxins (SAEs), 
superantigen, superantibody, basophil 
 
Abbreviations used 
CDR: complementarity-determining region 
CRSwNP: chronic rhinosinusitis with nasal polyps 
ELISA: enzyme-linked immunosorbent assay 
Fab: fragment antigen-binding 
FACS: fluorescence activated cell sorting  
FcεRI: Fc epsilon receptor I 
FR: framework region 
IGHV: immunoglobulin heavy-chain variable region genes 
IGKV: immunoglobulin kappa chain variable region genes 
IGLV: immunoglobulin lambda chain variable region genes 
IgE: immunoglobulin E 
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IgG1: immunoglobulin G subclass 1 
RT-PCR: reverse transcription polymerase chain reaction  
OVA: ovalbumin 
SAE: Staphylococcal aureus enterotoxin 
SEA-SEE: Staphylococcal enterotoxin A-E 
SIT: specific allergen immunotherapy 
SPR: surface plasmon resonance 
TCR: T cell receptor 
VL: variable region of light-chain 
VH: variable region of heavy chain 
  
INTRODUCTION 
Staphylococcus aureus (S. aureus) and its superantigens are implicated in the 
intense inflammatory processes of the upper and lower airway in allergic diseases.1 
These superantigens, in particular SAEs, are strongly associated with CRSwNP, 
particularly in the sub-population of AERD patients, as well as with allergic rhinitis, 
asthma and atopic dermatitis.2-5 SAEs are a family of structurally related proteins 
comprising different serological types: e.g. SEA, SEB, SEC, SED, SEE (up to SEU) and 
toxic shock syndrome toxin-1 (TSST-1).6 SAEs are potent T cell superantigens, 
causing polyclonal activation of up to 25% of certain T cell populations by 
interacting with a common β-chain structural framework region in the T cell 
receptor (TCR),7, 8 rather than the CDRs, which recognize specific antigenic 
peptides bound to MHC. The activity of SEA and SED on B cells in vitro suggests that 
they may also act as B cell superantigens by binding to the common structural 
framework regions in the immunoglobulin heavy-chain variable (VH) domains 
shared by immunoglobulins with different CDRs,9-11 as previously shown for 
Staphylococcal protein A (SpA).12-14 This might increase the polyclonality of the B 
cell repertoire in CRSwNP and allow S. aureus to escape immune surveillance.15, 16 
 
Nasal polyps in patients with CRSwNP are inflammatory outgrowths of the 
paranasal sinus mucosa, generally characterized by T helper 2 (Th2) inflammation, 
local immunoglobulin production and eosinophil infiltration driven by IL-5 and 
eotaxin.17-20 Up to 100% of AERD patients express anti-SAE IgEs in their nasal 
polyp homogenates and often have a higher prevalence of comorbid asthma and 
eosinophilic inflammation.17, 21-23 and IgEs from nasal polyps activate basophils 
in response to allergens and SEB in vitro.15 SEB acts as a human T cell superantigen 
in vivo to cause the symptoms of atopic dermatitis.24 Basophils isolated from atopic 
dermatitis patients with anti-SAE IgE in their sera, but not from healthy controls, 
were responsive to SAEs.25 Although anti-SAE IgE can be detected in the circulation 
of patients with CRSwNP, B cells expressing this IgE are confined to the nasal 
mucosa, suggesting a role in sinonasal inflammation.17 Whether the SAEs bind to 
CDRs and/or framework regions is addressed in the present work. 
 
Antibody production in nasal polyps of CRSwNP patients is driven by local 
activation and differentiation into plasma cells of B cells on exposure to various 
aeroallergens and microbial antigens.26, 27 Thus, nasal polyps removed from AERD 
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patients provide a unique source of tissue to study how SAEs may shape the local 
antibody repertoire. In the first study of this kind, we used an efficient single-cell 
RT-PCR method to clone and express antibodies from single SAE-specific B cells 
isolated the nasal polyps of three AERD patients and tested their primary function in 
effector cell activation.  
  
METHODS 
  
Patient samples 
Nasal polyps and sera were collected from three AERD patients (HPK-014, HPK-016, 
HPK-018) at the Royal National Throat Nose Ear Hospital, London, UK. The patients 
were male, mean age 56 years. Only Patient HPK-014 had positive skin prick tests to 
aeroallergens. The ethical committee representing the Royal National Throat Nose 
Ear Hospital approved the study, and all patients gave their written informed 
consent before the study commenced. 
 
Measurement of IgE to SAEs in sera and nasal polyp homogenates 
Detailed methods for processing sera, and nasal polyp homogenates are available in 
the Online Repository. All sera from blood samples and homogenates from nasal 
polyps were assayed for total IgE and specific IgEs to SEA, SEB, SEC1, SED, SEE and 
TSST-1, by the UNICAP system (Phadia, Uppsala, Sweden) (Table E1). 
 
Single B cell sorting by FACS and single-cell RT-PCR of immunoglobulin cDNA  
Single cell suspensions from frozen nasal polyp samples were prepared by one hour 
digestion with 1 mg/mL of hyaluronidase (Sigma-Aldrich, St Louis, Mo) and 1 
unit/mL Liberase TL (Roche) at 37°C. Samples were stained for CD19, CD138, SEA, 
SED and SEE. SAE-specific single B cells were FACS-sorted into 96-well PCR plates 
for cDNA synthesis and immunoglobulin expression cloning as IgG1. Full details of 
the cloning and expression strategy are available in the Online Repository (Figure 
E1 and Table E2). 
 
Antibody cloning, expression and purification 
SEA, SED and SEE-specific antibodies were expressed in human embryonic kidney 
293T cells (ATCC, Manassas, VA) as IgG1. Large-scale production of IgE, IgG1 and 
IgG1 Fabs was carried out using Expi293 cells (Invitrogen, Carlsbad, CA). The IgG1 
antibodies were purified by protein A-Sepharose (GE Healthcare, Pittsburgh, PA), 
the IgE antibodies by omalizumab-coupled NHS-activated Sepharose (GE 
Healthcare), and the IgG1 Fabs by LambdaFabSelect agarose (GE Healthcare). Anti-
SAE IgG1 antibodies were identified in culture supernatants by routine ELISA 
(Figure 2) and their purity was estimated by SDS-PAGE under reducing conditions 
(Figure E2). Further details are available in the Online Repository. 
 
Sequence analysis of the monoclonal immunoglobulin genes  
Immunoglobulin gene sequences were analyzed using the IMGT/V-Quest tool,28 
allowing identification of their clonal signatures (unique CDR3 sequences), germline 
V, D and J genes, and somatic mutations. The sequences are available in GenBank 
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(http://www.ncbi.nlm.nih.gov/genbank) and their accession numbers are listed in 
Table E4. 
 
Surface plasmon resonance  
Surface plasmon resonance using a Biacore T200 instrument (GE Healthcare) was 
performed to determine binding specificity, kinetics and affinity of the antigen-
antibody interactions. Further details are available in the Online Repository. 
 
Basophil degranulation assay 
Degranulation of cells of the rat basophilic cell line, RBL SX-38, which stably 
expresses the α, β and γ chains of human FcεRI,29 was used as a routine method to 
measure of the functionality of the SAE-specific antibodies. Further details are 
available in the Online Repository. 
 
  
RESULTS 
 
Cloning of anti-SAE antibodies 
Three AERD patients, HPK-014, HPK-016 and HPK-018, with titers of specific anti-
SAEs in their serum or nasal polyp homogenate were studied (Table E1). Specific 
IgEs to six common SAEs (SEA, SEB, SED, SEE, SEC and TSST-1) were detected in all 
three homogenate samples and in the serum of HPK-018, and to three SAEs (SEA, 
SEE and TSST-1) in the serum of HPK-14, whereas none were detected in the serum 
of HPK-016. The percentages of the anti-SAE IgEs were approximately ten-fold 
higher in the homogenates compared to the sera, ranging from 0.38 to 2.35% and 
0.03% to 0.31%, respectively (Table E1). 
 
Viable SAE-positive B cells (SAE+CD19+CD138-7-AAD-) identified by FACS (Figure 
1) were sorted into individual wells of 96-well plates. SAE-bound B cells accounted 
for 0.18%, 0.08%, and 0.25% of the nasal polyp B cell population of HPK-014, HPK-
016, and HPK-018, respectively (Table E3). “Matched” immunoglobulin VH and VL 
(κ or λ) DNA pairs were amplified from the cDNAs of 37 SAE+CD19+CD138- single B 
cells (18 from HPK-014, 6 from HPK-016 and 13 from HPK-018) (Figure E1). Of 
these 37 VH sequences obtained, 23 were from γ chains and 14 were from α chains. 
No VH sequence was obtained from ε chains. The VH genes used in these 37 VH 
sequences consisted of 12 VH1 (32.43%), 13 VH3 (35.14%), 6 VH4 (16.22%), 5 VH5 
(13.51%), and 1 VH6 (2.7%). Three (HPK014_2D6, HPK018_2A11 and 
HPK018_2C10) of the 37 B cells expressed both a κ and a λ chain. Of 40 VL 
sequences obtained, 25 were from λ chain and 15 were from κ chain. All 37 B cells 
represented different clones, ascertained by their unique CDR-H3 sequences (data 
not shown). We expressed all 40 of the putative SAE-specific matched variable 
regions as human IgG1 antibodies. 
 
Identification and sequence analyses of anti-SAE antibodies 
All 40 antibodies, expressed as IgG1, were assayed for the six SAEs detected in the 
nasal polyp homogenates by ELISA. Only SEA-, SED- and SEE-specific antibodies 
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could be identified, consistent with screening the B cells for only these specificities. 
Two anti-SEA antibodies, HPK018_1B6 (IgA1, VH1-46) and HPK016_1F3 (IgG1, 
VH1-69), two anti-SED antibodies, HPK014_1A4 (IgA2, VH3-34) and HPK018_2D6 
(IgA1, VH3-49), and two anti-SEE antibodies, HPK014_1G2 (IgA1, VH3-30) and 
HPK016_203 (IgG4, VH5-51) were identified (Figure 2). The germline 
immunoglobulin variable genes and isotypes used by those six antibodies are shown 
in Table E4. We refer to these antibodies below as the anti-SEA antibodies 1B6 and 
1F3, the anti-SED antibodies 1A4 and 2D6, and the anti-SEE antibodies 1G2 and 203. 
 
The V(D)H rearrangement and CDR-H3 signatures of the six anti-SAE antibodies are 
shown in Table E4. A higher frequency of λ light-chains (5/6) was found when 
compared to that in human peripheral blood B cells (1/5).30 Sequence alignments 
of six antibodies against their most closely related germline VH and VL gene 
sequences revealed a relatively high frequency of amino acid replacements in 
framework regions of VH and VL chains (Figure E3). 
 
Specificity and affinity of purified anti-SAE antibodies 
ELISA was used to determine the specificity of the purified recombinant IgG1 
antibodies with the SAEs (Figure 3A-C and results not shown). The 1G2 and 203 
antibodies were specific for SEE, although both displayed cross-reactivity with SEC1 
(27% amino acid sequence homology with SEE)31 to a different extent, rather than 
the more homologous SEA and SED (81% and 54% sequence homology with SEE, 
respectively).31 1F3 was specific for SEA but was not cross-reactive with SEE. All 
three antibodies exhibited high affinity for their cognate SAEs, demonstrating low 
nanomolar binding affinities as measured from the kinetics of interaction with 
specific SAEs by SPR (Figure 3D-F). 
 
Anti-SEE IgE mediates SEE-induced basophil degranulation  
To examine the activities of the corresponding anti-SAE IgEs, the γ1 chain constant 
region of the IgG1 antibodies was substituted with the human ε constant region and 
the resulting IgEs were expressed and purified (Figure E2B). Basophil degranulation 
activities of the six anti-SAE IgEs in the presence of the cognate SAE are shown in 
Figure 4.  
 
Conventional antigen binding via CDRs to two identical receptor-bound monoclonal 
IgE molecules, each of which recognizes a single epitope in a monomeric antigen, 
should not induce cross-linking of FcεRI on the surface of basophils to cause 
basophil degranulation. The anti-SEAs (Figure 4A) and the anti-SEDs (Figure 4B) 
behaved as expected, whereas both anti-SEE IgEs, 1G2 and 203, were active in this 
assay (Figure 4C). Basophil activation would require either two identical epitopes in 
the SEE because it formed a dimer like SED32 or two independent epitopes in an 
SEE molecule if it were a monomer. A recent crystal structure of SEE in a complex 
with TCR revealed a monomeric structure.33 Thus, we conclude that SEE has two 
distinct and non-overlapping epitopes that explains this activity; this is illustrated 
and discussed below in Figure 7A. SEC1 did not trigger 1G2 or 203 IgE-mediated 
basophil degranulation, although both show cross-reactivity to SEC1 (Figure 4D).  
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Anti-SEE antibodies bind to non-overlapping epitopes on SEE 
To map the epitopes of anti-SEE 1G2 and 203 antibodies on SEE, we carried out 
“sandwich” binding assays by ELISA and SPR. ELISA revealed that saturation of the 
1G2 binding site, achieved through addition of SEE to immobilized 1G2 Fab and IgE, 
did not prevent binding of 203 IgG1 (Figure E4). Also, SPR revealed that binding of 
saturating concentrations of 1G2 IgG1 to immobilized SEE did not prevent the 
simultaneous binding of soluble 203 IgG1 (Figure 5A). The reverse was also 
observed: after saturating all of the 203 binding sites on immobilized SEE, 1G2 IgG1 
could still bind with high affinity (Figure 5B). Both ELISA and SPR assays confirmed 
that the two anti-SEE antibodies bind to non-overlapping epitopes on SEE. 
 
Anti-SEE IgG1 modulates IgE-mediated degranulation 
To characterize the interplay of the different anti-SEE isotypes, IgE and IgG1, they 
were tested in pairwise combinations in basophil degranulation assays. As expected, 
due to competition for epitope binding to SEE, the 1G2 IgG1 inhibited SEE-induced 
degranulation of basophils sensitised with the 1G2 IgE, and the 203 IgG1 inhibited 
degranulation of basophils sensitised with the 203 IgE (Figures 6A).34, 35 As also 
expected, the IgG1 that recognized the non-overlapping epitope on IgE enhanced 
degranulation (Figures 6A) by cross-linking two SEE molecules bound to adjacent 
receptor-bound IgE molecules; this is illustrated below in Figure 7B. The 1F3 
antibody, specific for SEA, had no such effects, demonstrating that antigen specificity 
is crucial for the modulation of IgE activity by IgG1. 
 
Paradoxical enhancing activity of anti-SEE Fabs  
We repeated the pairwise assays using the two anti-SEE IgG1 Fabs (Figure 6B). As 
expected, the Fabs exhibited the same inhibitory activity as the whole IgG1 
antibodies (due to competitive inhibition), when Fab and IgE were of the same 
specificity. Cross-linking of adjacent IgE-SEE complexes on the basophil surface 
cannot occur with a monomeric Fab, even one that binds to the non-overlapping 
epitope. Paradoxically, the Fab recognizing the non-overlapping epitope retains the 
enhancing activity of the whole IgG1 (Figure 6B).  
 
Figure 7C illustrates the mechanism by which receptor cross-linking may occur. We 
suggest that high-affinity binding (Figure 5) of receptor-bound anti-SEE IgE to SEE 
through its CDRs, to the epitope represented in green (Figure 7C), facilitates 
subsequent low-affinity binding through a site on SEE, represented in red, that binds 
to a framework region of an adjacent IgG (or Fab) that recognizes a non-overlapping 
SEE epitope, represented in blue. We call such an antibody, in principle of any 
isotype, which acts synergistically to enhance IgE effector functions, a 
“superantibody”. 
 
DISCUSSION 
Several human monoclonal antibodies against specific allergens have been obtained 
from allergic patients by phage display,36-40 EBV transformation of peripheral 
blood mononuclear cells,41 or single-cell RT-PCR.34 Besides, many groups have 
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generated anti-SEB monoclonal antibodies by either mouse hybridoma or phage 
display, and pursued their use as therapeutic agents.42, 43 In earlier work we 
produced a recombinant allergen (Phl p 7)-specific antibody with the native 
(“matched”) heavy- and light-chain using single cell PCR.34 To the best of our 
knowledge, the present work is the first report of recombinant anti-SAE antibodies 
containing matched heavy- and light-chains cloned by using single-cell RT-PCR. We 
produced six anti-SAE antibodies that bind to SAEs with high affinity: 2B6 and 1F3 
for SEA, 1A4 and 2D6 for SED and 1G2 and 203 for SEE. The VH regions of 1F3 and 
203 were derived from single IgG-expressing B cells, and 1B6, 1A4, 1G2 and 2D6 
from single IgA-expressing B cells, present in the nasal polyps from three patients 
with CRSwNP (Table E4). The antibodies were first expressed as IgG1 and then 
converted to IgE and Fab. 
 
We began with the hypothesis that SAEs may act as B cell superantigens as well as T 
cell superantigens. Indeed, this suggestion has often been made before. It is 
consistent with the evidence that SEA and SED bind weakly to immunoglobulins 
bearing VH3 and VH4, respectively.10, 11 Several authors have demonstrated the 
overabundance of VH5 in IgE, suggesting that such a B cell superantigen(s) may 
recognize member(s) of this VH family.44-47 Low-affinity and promiscuous binding 
to the TCR variable β (Vβ)-chains are characteristics of T cell superantigens, which 
include SEA, SED and, notably, SEE.7, 8 SEE binds to six different human Vβ 
chains.48 We have shown here that SEE can indeed behave as a B cell superantigen 
by interacting with IgE molecules both conventionally via CDRs and 
unconventionally through framework regions (Figure 7A).  
 
ELISA assays used to select the six antibodies described in the present study would 
not have detected weak binding of SAEs to the framework regions. However, strong 
binding of SAEs to the CDRs in the context of a cell would facilitate weak binding to 
the framework regions due to an increase in avidity. Binding of SAEs to the 
framework regions of BCRs may also contribute to somatic hypermutation and 
affinity maturation of antibodies. Coker et al. found 75% of mutational hot spots in 
the framework regions of IgE and IgA expressed by B cells in the nasal mucosa 
exposed to S. aureus commensal infections.46 Superantigen-driven selection at the 
stage of local affinity maturation may explain the high frequency of mutations in the 
framework regions of our cloned anti-SAEs (Figure E3). 
 
Due to real world limitations of the experimental methods used in this study, we 
have not obtained definitive evidence for the proposed interactions (Figure 7). First, 
IgE-expressing antibodies were not among the 40 recombinant antibodies that we 
expressed; this was not surprising owing to the extremely low abundance of IgE- 
compared to IgG- and IgA-expressing B cells49. Secondly, although we have shown 
that IgG-expressing B cells undergo local switching to IgE in nasal polyps from 
patients with CRSwNP and in the respiratory tract mucosa in allergic diseases,50-53 
1G2 and 203 antibodies came from different patients. We would have needed IgE 
related to at least one of them, and both antibody isotypes from the same individual, 
to prove the existence of “superantibodies” in this AERD cohort. Nevertheless, in 
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unpublished work using next-generation sequencing of B cell repertoires in nasal 
polyps we have observed as many as 17/10,000 IgE sequences related to IgG or IgA. 
In the B cell repertoire of HPK014 we were able to identify IgE relatives of two 
recombinant IgG1 antibodies (A: HPK014_1A6 and B: HPK_014 2A8; Figure E5), 
although these two IgG1 clones were not among the six clones that exhibited high-
affinity for the SAEs (Figure 3).  
 
One of the antibodies, 203, was originally an IgG4 and, interestingly, expresses VH5-
51, the only one of two VH5 family members that is overexpressed in IgE (Wu et al., 
unpublished results) and a suspect for binding in a superantigen-like manner.46 
The other antibody, 1G2, was originally an IgA1 and expresses a member of the VH3 
family (VH3-30, Table E4). The CDRs differ between 203 and 1G2, so it may be that 
SEE binds promiscuously to both VH5 and VH3 framework regions. Structural 
studies are required to define the epitopes in SEE. 
 
It was previously shown by X-ray crystallography that SpA is recognized by a 
rheumatoid factor antibody in a superantigen-dependent manner, in which SpA 
interacts with the framework residues of the VH3 domain.14 We believe the anti-
SEE “superantibodies” presented here may be the first antibodies shown to have 
both conventional antigen- and superantigen-binding sites and thus to have 
“superantibody” activity.  
 
The ability of the anti-SEE IgG1 and their Fab to inhibit the activity of basophils 
sensitised by the related IgE resembles the blocking activities of IgG4 or IgA in 
specific allergen immunotherapy (SIT).34, 35, 54 Blocking IgG antibodies have been 
developed by many groups for therapeutic use as anti-toxins. Nearly all anti-toxin 
antibodies and all isolated anti-SEB antibodies are blocking, as opposed to 
enhancing antibodies.42, 43, 55 SAE vaccination has been investigated with 
encouraging success for efficacy in treating infections with S. aureus.56, 57 Whether 
anti-SEE IgGs from the present study may be similarly efficacious could be 
determined, but a combination of anti-SAEs may be even more efficacious than any 
single anti-SAE. 
 
To the best of our knowledge, 1G2 and 203 are the first examples of enhancing anti-
SAE antibodies. However there is a precedent in the case of the antibody BAB2 
against birch pollen allergen Bet v 1, a dominant birch pollen allergen.58 BAB2 and, 
notably, its Fab, enhanced binding of Bet v 1 to IgE and caused immediate type 
hypersensitivity reactions in human skin. The authors suggested that enhancing 
antibodies could account for the failure of SIT.58-60 Although enhancing antibodies 
are relatively rare, they may be important because their activity may “win” in 
competition with an excess of blocking antibodies. 
 
In previous studies, it has been demonstrated that certain antibodies against a 
specific allergen are more frequently observed than others in atopic patients; such 
allergens are said to be “dominant”, e.g. Der p 1 and Der p 2 in house dust mite 
allergy.61, 62 These allergens usually have multiple epitopes, allowing more 
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extensive cross-linking of the IgE-FcεRI complexes on effector cells. In this case, 
non-competitive allergen-specific IgG or IgA, likely present in much higher 
concentrations than the IgE, may be able to enhance cell activation if the 
configuration of the two sites and the resulting distance between cross-linked 
complexes is favorable (Figure 7B). 
 
SEE was first documented in a case of food poisoning.63 It was later identified as a 
26.4 kDa single-chain protein belonging to the group III superantigens (the SEA 
superfamily), having strong homology to SEA and SED as stated above. SEE has been 
shown to be a potent enterotoxin and a polyclonal activator of T cells64, 65 and 
binds promiscuously to multiple human TCR Vβ chains.48 Anti-SEE IgE was 
demonstrated in 16.7% of nasal polyps, compared to 0% in control tissue as well as 
in all nasal polyp samples from all three CRSwNP patients in the present study.17 
Sequence comparison of SEA, SEC1, SED and SEE and inspection of the SEA and SEE 
crystal structures32, 33 suggest that certain surface-exposed residues could alter 
the electrostatic potential, or shape, of the enterotoxin surface, rendering SEE and 
SEC1 different from SEA and SED, thereby contributing to the cross-reactivity of the 
203 antibody. 
 
Basophils were activated to release granular mediators by allergens and SEB when 
sensitised by IgE in homogenates from the nasal polyps of patients with CRSwNP in 
vitro,15 indicating the functionality of IgE antibodies in nasal polyps. Thus, the 
putative anti-SEE IgEs, 1G2 and 203, in patients HPK_014 and HPK_016, together 
with the potential IgG4 or IgA1 precursors, may activate a variety of effector cells 
and contribute to the pro-inflammatory environment in the patients’ nasal polyps. 
This is compatible with the evidence from the work of Gevaert et al. that 
omalizumab is therapeutic in CRSwNP,66 although an earlier study failed to show 
efficacy.67 It should also be noted that IgG and IgA “superantibodies” activities 
independent of IgE. 
 
In summary, our results provide proof of concept that SAES may act as B cell 
superantigens, and that anti-SAE antibodies of any isotype may behave as 
“superantibodies”. We have isolated antibodies with potential “superantibody” 
activity from nasal polyps of patients with AERD, a highly inflammatory Th2 disease. 
However, similar antibodies may occur in allergic diseases and asthma associated 
with commensal S. aureus infections and dominant allergens. 
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Figure Legends 
Figure 1. Isolation of SAE+ B cells from nasal polyps by FACS 
Cells were labeled with a mixture of biotinylated SEA, SED and SEE, PE-coupled anti-
CD138, APC-coupled anti-CD19 and 7-AAD. The lymphocyte population was selected 
for size and granularity (A). Live B cells were identified as CD19+7-AAD- cells (B). 
FMO (fluorescence minus one) control (C) and No SAE control (D) were used to 
select SAE+CD19+CD138-7-AAD- cells, which constituted 0.25% of the total B cell 
population (E). No SAE control indicates that the cells were stained with all 
fluorescent antibodies and streptavidin-FITC but without biotinylated SAEs, while 
FMO control stained with all antibodies but without streptavidin-FITC. 
 
 
Figure 2. Six of the expressed antibodies exhibited SAE binding. 
The cleared supernatants collected from 293T cells, separately transfected with 40 
IgG1 expression plasmids, were tested for reactivity with SEA, SEB, SEC1, SED, SEE, 
TSST-1 and OVA by ELISA. An antibody with specificity to a particular SAE was 
identified with an absolute OD value higher than control IgG. The antibodies 
selected for further studies are highlighted in bold. Control IgG is a human IgG1 with 
VH4 and Vκ. We expected to select only high-affinity binders by ELISA due to the 
low sensitivity of this assay. 
 
 
Figure 3. Specificity and high affinity of anti-SEE and anti-SEA antibodies. 
(A-C) Recombinant IgG1 antibodies 1G2, 203 and 1F3 at the indicated 
concentrations were tested for binding to SEA, SEB, SEC1, SED, SEE and TSST-1 by 
ELISA. (D-F) Binding kinetics was characterized by SPR using biotin-labeled SEE or 
SEA immobilized on a streptavidin-coated sensor chip. Purified antibodies were 
injected at the indicated concentrations, followed by dissociation. 
 
 
Figure 4. Anti-SAE IgEs mediate SAE-induced basophil degranulation  
RBL SX-38 cells were sensitised with (A) anti-SEA IgE 1B6 or 1F3, (B) anti-SED IgE 
1A4 or 2D6, or (C) anti-SEE IgE 1G2 or 203 and stimulated by the cognate SAE or 
anti-IgE as a positive control. (D) RBL SX-38 cells were sensitised with the indicated 
anti-SAE IgEs and stimulated with the indicated SAEs. Degranulation was assayed by 
β-hexosaminidase release. 
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Figure 5. Anti-SEE antibodies bind to distinct, non-overlapping epitopes. 
250 nM 1G2 IgG1 was injected onto a sensor chip coated with SEE for 3 minutes, 
immediately followed by a 3 minute injection of either running buffer (black), 500 
nM 1G2 IgG1 (blue), or 100 nM 203 IgG1 (red) (A). Following regeneration of the 
chip by glycine-HCl (pH 2.5), the experiment was performed in reverse, with a 3 
minute binding of 100 nM of 203 IgG1, followed by a 3 minute injection of either 
buffer (black), 500 nM 203 IgG1 (red), or 100 nM 1G2 (blue) (B). 
 
 
Figure 6. The unrelated anti-SEE IgG1 or Fab enhances anti-SEE IgE-mediated 
basophil degranulation.  
 
RBL SX-38 cells were sensitised with anti-SEE or anti-SEA IgE antibodies and 
stimulated with SEE in the presence of anti-SEE (+1G2/+203) or anti-SEA (+1F3) 
IgG1 (A) or Fab (B). Dotted lines represent positive (upper; anti-IgE) and negative 
(media only) controls. Degranulation was assayed by β-hexosaminidase release. 
 
 
Figure 7. Schematic representation of proposed antibody and “superantibody” 
activities 
 
(A) A monomeric SEE molecule cross-links two FcεRI-bound IgE molecules on the 
surface of a basophil (receptor not shown) via two epitopes: the “green” site is 
recognized conventionally by the CDRs of the IgE antibody, and the “red” site 
interacts with the framework regions of the IgE V region in a “superantigen” 
manner. (B) An IgG1 antibody that recognizes a non-overlapping “blue” epitope 
cross-links two FcεRI-bound IgE molecules that recognize the “green” epitope; both 
blue and green epitopes are recognized conventionally by the CDRs. (C) Since the 
IgG1 Fab (highlighted in darker blue) can also cross-link FcεRI-bound IgE, we 
propose that two monomeric SEE molecules can effect this: one is recognized 
conventionally via the two non-overlapping (green and blue) epitopes by two 
unrelated anti-SEEs; the other involves the “superantigen” site (red). While the 
cross-linking ability of the Fab reveals the interactions that underpin this proposed 
mechanism, the whole antibody may act not only in the manner depicted in (B), but 
also that shown in (C). The antibody, exhibiting the ability to recognize two SEE 
molecules simultaneously through both CDRs and framework regions, we call a 
“superantibody”. 
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METHODS 28 
Preparation of sera and nasal polyp homogenates  29 
Blood samples were allowed to clot at room temperature for one hour, centrifuged at 2,000×g for 30 
20 min and the serum was separated and stored at -70 °C. PBS containing protease inhibitor 31 
cocktail (Roche, Mannheim, Germany) was added to snap-frozen nasal polyp specimens at 1 mL 32 
per 0.1 g tissue. The tissues were homogenized using a TissueLyser (Qiagen, Hilden, Germany) 33 
for 2 min at 30 Hz until disrupted, the homogenates were centrifuged at 15,000×g for 20 min at 4 34 
°C, and the supernatants were collected and stored at -70 °C. 35 
 36 
Single cell sorting by FACS 37 
After dispersion by enzymatic digestion of nasal polyps, cells were washed with complete RPMI 38 
medium (10% fetal bovine serum in RPMI medium) to remove the enzymes, filtered through a 39 
40-mm cell strainer, and finally resuspended at a concentration of 1x106 cells/mL in FACS 40 
buffer [5% normal goat serum (Invitrogen, Carlsbad, CA) and 2 mM EDTA in PBS]. Then, cells 41 
were stained by PE-coupled anti-CD138 (BioLegend, San Diego, CA), APC-coupled anti-CD19 42 
(BD Biosciences, San Jose, CA), 7-AAD (eBioscience, San Diego, CA), and biotinylated SAEs 43 
(Toxin Technology, Sarasota, FL) in FACS buffer. Biotinylated SEA, SED, and SEE were 44 
simultaneously used for labeling cells at each concentration of 10 µg/mL and detected by FACS 45 
using streptavidin-Alexa-488 (Invitrogen) at a dilution of 1/1000.  46 
 47 
Single-cell RT-PCR 48 
Single SAE+CD19+CD138-7-AAD- B cells were directly sorted into 96-well PCR plates 49 
(Fermentas, Vilnius, Lithuania) containing 18 µL/well of ice-cold 1× RT buffer (Invitrogen) 50 
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containing 0.1% Triton-X 100, 10 mM DTT, 300 ng random hexamers (Invitrogen), 0.5 mM 51 
dNTP mix (Fermentas), 40 U Ribolock RNase Inhibitor (Fermentas) on a FACSAria II cell 52 
sorter (BD Biosciences). Fifty units of Superscript III reverse transcriptase (Invitrogen) were 53 
added and then reverse transcription was performed at 42 °C for 10 min, 25 °C for 10 min, 50 °C 54 
for 60 min and 85 °C for 5 min. 55 
Primer nucleotide sequences to cover all known V-region genes and reverse primers specific for 56 
κ and λ constant regions were as previously described.1 Reverse primers for γ, α, and ε constant 57 
regions were Cγ1 (5’-GGAAGGTGTGCACGCCGCTGGTC-3’), Cε1 (5’-58 
GGTTTTGTTGTCGACCCAGTCTG-3’), and Cα1 (5’-TGGGAAGTTTCTGGCGGTCACG-59 
3’) as primary primers for the first-round PCR, and Cγ2 (5’- 60 
GTTCGGGGAAGTAGTCCTTGAC-3’), Cα2 (5’- GTCCGCTTTCGCTCCAGGTCACACT-61 
3’), and Cε2 (5’- TGGCATAGTGACCAGAGAGCGTG-3’) as nested primers for the second-62 
round PCR, respectively. All PCRs were carried out by proof-reading PhusionTM DNA 63 
polymerase (Fermentas). Second-round PCR products were sequenced after purification by 64 
QIAquick PCR purification kit (Qiagen, Hilden, Germany). 65 
 66 
Recombinant antibody cloning and expression 67 
Purified second-round PCR products were used as a PCR template for amplifying DNA inserts 68 
by V-region and J-region specific primers containing an overhang sequence (Table EI) that is 69 
homologous to the bases at one end of adjacent DNA fragment of pIgG1(κ) or pIgG1(λ) vectors.2 70 
Purified DraIII/NheI- and BspEI/NheI-digested DNA fragments from pIgG1(κ) and pIgG1(λ) 71 
vectors were used a template for amplifying “backbone insert” by CL forward primers, SL-Cκ+ 72 
or SL-Cλ+, and an IgG leader reverse primer, SL-IgG Leader- (Figure E1 and Table E2), 73 
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respectively. All PCR products above were synthesized by Phusion DNA polymerase and 74 
purified by QIAquick PCR purification kit. The linear pIgG1(κ) and pIgG1(λ) vectors were 75 
prepared by double digestion with DraIII/NheI and BspEI/NheI, respectively, and purified by 76 
agarose gel electrophoresis and gel extraction (Gel purification kit, Qiagen). The assembly of 77 
antibody expression vector was carried out by homologous recombination using a Geneart 78 
Seamless assembly kit (Invitrogen) according to vendor’s instructions as shown in Figure E1.  79 
 80 
Briefly, 20 ng of paired VH and VL DNA segments, 50 ng of backbone insert, and 100 ng of 81 
linear vector were combined with Seamless enzyme mix and incubated at room temperature for 82 
30 min. The assembly products were immediately transformed into competent E. coli (One Shot 83 
Top 10, Invitrogen) and transformants were analyzed for the presence of DNA inserts by colony 84 
PCR. The plasmid DNA of positive clones were purified and sequenced to ensure no base 85 
mutations and correct recombination.  86 
 87 
To produce cloned antibodies on a small scale for validating their binding specificities, human 88 
embryonic kidney 293T cells (ATCC, Manassas, VA) were seeded in 6-well plates. Transient 89 
transfections were performed at 80% cell confluency by linear polyethylenimine (PEI) with an 90 
average molecular weight of 25 kDa (Polysciences, Warrington, PA) as a transfection reagent. 91 
The cells were cultured for 2 days before the supernatants were harvested and analyzed by 92 
ELISA for SAE binding reactivity. The concentrations of recombinant IgG1 antibodies released 93 
into the supernatants of transfected 293T cells were measured by ELISA using human IgG 94 
Quantitation Kits (Bethyl Laboratories, Montgomery, TX). To construct IgE and Fab expression 95 
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vectors, the γ1 constant regions of SAE-specific antibody expression vectors were replaced by 96 
the ε constant region or the CH1 domain of γ1 constant region, respectively. 97 
 98 
ELISA for SAE-specific antibodies in culture supernatants  99 
Microtitre plates were coated with 2 µg/mL of each SEA, SEB, SEC1, SED, SEE, and TSST-1 100 
(Toxin Technology) or OVA (50 µL/well) overnight at 4°C and blocked with 200 µL of assay 101 
diluent (0.5% BSA, 0.05% Tween-20 and 0.01% thimerosal in PBS). Bound IgG1 antibodies 102 
were detected by HRP-conjugated goat anti-human IgG Fc antibody (Jackson ImmunoResearch, 103 
West Grove, PA), and developed with NeA-Blue TMB substrate (Clinical Science Products, 104 
Mansfield, MA). 105 
 106 
Basophil degranulation assay 107 
RBL-SX38 cells were typically grown in complete MEM medium as previously described.3 One 108 
day prior to a planned experiment, RBL SX-38 cells were seeded at 6x105 cells/mL (500 µL per 109 
well) in 48-well plates. After an overnight incubation, 250 µL of complete MEM medium 110 
containing SAE-specific IgE at 1 µg/mL was added to sensitise the cells. After 2-hour incubation 111 
at 37°C, each well was washed twice with 500 µL of pre-warmed Tyrode’s buffer (135 mM 112 
NaCl, 5 mM KCl, 5.6 mM glucose, 1.8 mM CaCl2, 1 mM MgCl2, 20 mM HEPES, and 0.5 113 
mg/mL BSA, pH 7.3) and then 250 µL of Tyrode’s buffer containing SAEs at 1 µg/mL or 114 
polyclonal anti-human IgE antibody (Bethyl Laboratories, Montgomery, TX) at 3 µg/mL or 1% 115 
Triton X-100 was added to the cells. After a 30-min incubation in a 37 °C incubator, the culture 116 
media were collected and subjected to centrifugation at 300×g for 5 min at room temperature. 117 
Fifty microliters of cleared supernatants were transferred to each well of a 96-well black 118 
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OptiPlate (Perkin-Elmer, Waltham, MA) and then 50 µL of substrate solution [80 µM of 4-MUG 119 
(4-methylumbelliferyl-N-acetyl-d-glucosaminide; Sigma-Aldrich, St Louis, Mo) in 0.1 M citric 120 
acid buffer (pH 4.5)] was added into each well. The tape-sealed plate was incubated at 37◦C for 1 121 
hour and the reaction was terminated by adding 100 µL of glycine buffer (0.2 M glycine, 0.2 M 122 
NaCl, pH 10.7). The resulting fluorescence (excitation 355 nm; emission 460 nm) was measured 123 
by a Victor 3 fluorescence reader (PerkinElmer, Boston, MA). Measured values were expressed 124 
as percentages relative to the value of release (100%) obtained by lysing cells with 1% Triton X-125 
100. 126 
 127 
Surface Plasmon Resonance 128 
The purified and concentrated immunoglobulin solutions were quantified by a NanoDrop 129 
spectrophotometer (Thermo Scientific, Wilmington, DE) using absorbance at 280 nm and the 130 
protein concentration was calculated with the extinction coefficient of each antibody, which was 131 
predicted by conducting the computation of a ProtParam program 132 
(http://web.expasy.org/protparam/). Biotin-labelled SEE and SEA were immobilised on a 133 
streptavidin-coated sensor chip (GE Healthcare). Binding of SAE-specific IgG1 antibodies was 134 
measured at 25°C using a 3-minute association phase and a 10-minute dissociation phase (unless 135 
otherwise specified in the Figure legend) in a concentration series ranging from 250 nM to 16 136 
nM. To detect simultaneous binding of two antibodies, one antibody was injected for 3 minutes 137 
followed by a 3-minute injection of the second antibody or buffer. Following regeneration with 138 
glycine-HCl (pH 2.5), the experiment was performed in reverse. Standard double referencing 139 
data subtraction methods were employed using a control surface (biotin alone).  140 
141 
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Figure Legends 
 
Figure E1. Cloning strategy for constructing recombinant IgG1 expression vector. Paired 
VH and VL regions from sorted single SAE-specific B cells were amplified by RT-PCR and 
sequenced as described in the Methods of Online Repository. Fifteen base pair homologous arm 
was introduced by PCR to permit cloning into pIgG1(κ) or pIgG1(λ) vectors by homologous 
recombination using the Seamless method as described in the Methods of Online Repository. 
Abbreviation: L, Leader; CL, constant region of light-chain; JL, J region of light-chain; JH, J 
region of heavy chain; SL, seamless. 
 
 
Figure E2. Purity of recombinant SAE-specific IgG1, IgE and Fab antibodies. 
All recombinant SAE-specific IgG1 (A), IgE (B) and Fab (C) antibodies were transiently 
expressed in Expi293F cells and purified by protein A, anti-IgE or LambdaFabSelect affinity 
chromatography, respectively. Five micrograms of each antibody were fractionated by 12% 
SDS-PAGE under reducing conditions before Coomassie Blue staining. 
 
 
Figure E3. Amino acid sequence alignment for six cloned SAE-specific antibodies against 
germline sequences. 
The V genes encoding the VH (A) and VL (B) of SAE-specific antibodies were identified by 
IMGT/V-Quest. Somatic hypermutations that resulted in amino acid changes are indicated. 
 
 
Figure E4. 1G2 and 203 bind to distinct epitopes on SEE. 
Each well of a 96-well ELISA plate was coated with 1G2 Fab or IgE antibodies at 1 µg/mL (50 
L/well), followed by saturating 1G2 antibody binding sites with SEE at 1 µg/mL (100 
L/well). The 1F3, 1G2 and 203 IgG1 antibodies were added to each well, followed by 
incubation with peroxidase-conjugated goat anti-human IgG.Fc. 
 
 
Figure 5E. Expressed single-cell IgG1 clones with IgE relatives identified by next 
generation sequencing of B-cell repertoire.  The immunoglobulin heavy-chain gene repertoire 
in the nasal polyps from HPK-014 patient were captured using next-generation sequencing 
(NGS) on the Illumina 2x300 MiSeq System and bioinformatically analysed (manuscript in 
preparation). The sequences in the HPK-014 NGS dataset were aligned with the recombinant 
IgG1 antibodies expressed from 18 FACS-sorted SAE-positive B cells (SAE+CD19+CD138-7-
AAD-) and their clonal relatedness was determined by the use of clone-specific CDR3 DNA 
motifs. Two clonal families were identified, showing two expressed recombinant IgG1 antibodies 
(A: HPK014_1A6 and B: HPK014_2A8; Sequence ID in blue) related to IgE (Sequence ID in 
red) and other IgG mutants in the HPK-014 NGS dataset. For illustration purposes, not all 
members of the clones isolated using NGS are shown.  
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Table E1. SAE-specific IgEs in serum and nasal polyp homogenate. 
 Serum  Nasal polyp homogenate 
 Total 
IgE  
Specific IgE  Total 
IgE  
Specific IgE 
Patient ID SEA SEB SED SEE SEC TSST-1  SEA SEB SED SEE SEC TSST-1 
HPK-014 89.3 0.17
a
 
(0.19%)b - - 
0.28 
(0.31%) - 
 0.16 
(0.18%)  26.1 
0.25 
(0.96%) 
0.12 
(0.46%) 
0.1 
(0.38%) 
0.13 
(0.5%) 
0.13 
(0.5%) 
0.21 
(0.8%) 
HPK-016 53.2 - - - - - -  8.1 0.11 (1.36%) 
0.11 
(1.36%) 
0.08 
(0.99%) 
0.09 
(1.11%) 
0.11 
(1.36%) 
0.19 
(2.35%) 
HPK-018 317 0.09 (0.03%) 
0.81 
(0.26%) 
0.78 
(0.25%) 
0.13 
(0.04%) 
0.05 
(0.02%) 
0.07 
(0.02%)  48 
0.59 
(1.23%) 
0.24 
(0.5%) 
0.31 
(0.65%) 
0.27 
(0.56%) 
0.32 
(0.67%) 
0.28 
(0.58%) 
a
 KU/L unit was introduced to express the level of IgE. 153 
b
 % of total IgE was the percentage of each SAE-specific IgE in total IgE. 154 
155 
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Table E2. Primers used for antibody cloning 156 
 157 
Primer Sequence 
VH cloning PCR  
SL-VH1/3/5f gttgctacgcgtgtcCTGAGCSAGGTGCAGCTGGTGSAGTC 
SL-VH1-3f gttgctacgcgtgtcCTGAGCCAGGTCCAGCTTGTGCAGTC 
SL-VH1-18f gttgctacgcgtgtcCTGAGCCAGGTTCAGCTGGTGCAGTC 
SL-VH1-24f gttgctacgcgtgtcCTGAGCCAGGTCCAGCTGGTACAGTCTG 
SL-VH2f gttgctacgcgtgtcCTGAGCCAGGTCACCTTGARGGAGTCTG 
SL-VH3-23f gttgctacgcgtgtcCTGAGCGAGGTGCAGCTGTTGGAGTCT 
SL-VH4f gttgctacgcgtgtcCTGAGCCAGSTGCAGCTGCAGGAGT 
SL-VH4-34f gttgctacgcgtgtcCTGAGCCAGGTGCAGCTACARCAGTGG 
SL-VH6f gttgctacgcgtgtcCTGAGCCAGGTACAGCTGCAGCAGTCA 
SL-VH7f gttgctacgcgtgtcCTGAGCCAGGTGCAGCTGGTGCAAT 
  
Vκ cloning PCR  
SL-Vκ1f ggctcccaggtgcacgatgtgACATCCAGWTGACCCAGTCTCC 
SL-Vκ2f ggctcccaggtgcacgatgtgATATTGTGATGACCCAGACTCCACTCT 
SL-Vκ3f ggctcccaggtgcacgatgtgAAATTGTGTTGACRCAGTCTCCAG 
SL-Vκ4f ggctcccaggtgcacgatgtgACATCGTGATGACCCAGTCTC 
SL-Vκ5f ggctcccaggtgcacgatgtgAAACGACACTCACGCAGTCTC 
SL-Vκ6f ggctcccaggtgcacgatgtgAAATTGTGCTGACTCAGTCTCCA 
  
Vλ cloning PCR  
SL-Vλ1-40/50/51f tccttgcttatgggtccggaGTGGATTCTCAGTCTGTGYTGACGCAGCC 
SL-Vλ1-36/44/47f tccttgcttatgggtccggaGTGGATTCTCAGTCTGTGCTGACTCAGCCA 
SL-Vλ2f tccttgcttatgggtccggaGTGGATTCTCAGTCTGCCCTGACTCAGCC 
SL-Vλ3f tccttgcttatgggtccggaGTGGATTCTTCCTATGAGCTGACWCAGCCA 
SL-Vλ3-19f tccttgcttatgggtccggaGTGGATTCTTCTTCTGAGCTGACTCAGGAC 
SL-Vλ4/5/9f tccttgcttatgggtccggaGTGGATTCTCAGSCTGTGCTGACTCAGCC 
SL-Vλ4-60/69f tccttgcttatgggtccggaGTGGATTCTCAGYCTGTGCTGACTCAATC 
SL-Vλ6f tccttgcttatgggtccggaGTGGATTCTAATTTTATGCTGACTCAGCCC 
SL-Vλ7/8f tccttgcttatgggtccggaGTGGATTCTCAGRCTGTGGTGACYCAGGAG 
SL-Vλ10f tccttgcttatgggtccggaGTGGATTCTCAGGCAGGGCTGACTCAGCC 
  
JH cloning PCR  
SL-JH1/4/5r gatgggcccttggtgctagcTGAGGAGACGGTGACCAGG 
SL-JH2r gatgggcccttggtgctagcTGAGGAGACAGTGACCAGGGT 
SL-JH3r gatgggcccttggtgctagcTGAAGAGACGGTGACCATTGTC 
SL-JH6r gatgggcccttggtgctagcTGAGGAGACGGTGACCGTG 
  
Jκ cloning PCR  
SL-Jκ1r tgcagccaccgtacgTTTGATTTCCACCTTGGTCCCT 
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SL-Jκ2r tgcagccaccgtacgTTTGATCTCCAGCTTGGTCCCT 
SL-Jκ3r tgcagccaccgtacgTTTGATATCCACTTTGGTCCCA 
SL-Jκ4r tgcagccaccgtacgTTTGATCTCCACCTTGGTCCCT 
SL-Jκ5r tgcagccaccgtacgTTTAATCTCCAGTCGTGTCCCTT 
  
Jλ cloning PCR  
SL-Jλ1r ggccttgggctgacctaggACGGTGACCTTGGTCC 
SL-Jλ2/3r ggccttgggctgacctaggACGGTCAGCTTGGTCC 
SL-Jλ6r ggccttgggctgacctaggACGGTCACCTTGGTGC 
SL-Jλ7r ggccttgggctgacctaggaCGGTCAGCTGGGTGC 
  
Backbone insert 
cloning PCR 
 
SL-Cκ+ CGTACGGTGGCTGCACCATC 
SL-Cλ+ GGTCAGCCCAAGGCCAACC 
SL-IgG Leader- GACACGCGTAGCAACAGCGA 
 158 
Homologous sequences to the bases at the one end of the adjacent DNA fragment are displayed 159 
in lower case. 160 
  161 
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Table E3. The cell populations of nasal polyp tissues. 162 
 163 
 HPK-014 HPK-016 HPK-018 
Lymphocytesa 10.1% (255,337) 7.42% (157,133) 17.2% (313,277) 
Live cells (7-AAD-)b 94.3% (239,878) 87.1% (136,067) 95.3% (297,159) 
Live B cells (CD19+7-AAD-)b 20.7% (52,717) 21.1% (33,024) 29.4% (91,607) 
SAE-positive cells (SAE+CD138-)c 0.18% (92) 0.08% (26) 0.25% (225) 
Plasma cells (SAE-CD138+)c 2.98% (1,573) 0.1% (34) 0.37% (339) 
a
 % of total nasal polyp cells 164 
b
 % of lymphocytes 165 
c
 % of total live B cells. 166 
167 
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Table E4. The germline immunoglobulin variable gene and CDR3 sequences of cloned VH and 168 
VL pairs in the SAE-specific antibodies 169 
The VH and VL DNA sequences of each clone are available in GenBank 170 
(http://www.ncbi.nlm.nih.gov/genbank) using and the accession numbers are indicated in the 171 
Table. 172 
 173 
Clone Name Isotype VH IGHV IGHD IGHJ CDR-H3 amino acids VL IGK(L)V IGK(L)J CDR-L3 amino acids 
HPK014_1A4 A (α2) KT369789 3-23 3-9 3 CAKKRRYDAVTGYLFDMW KT369790 4-1 (κ) 2 CQQFYSPAPYTF 
HPK014_1G2 A (α1) KT369791 3-30 6-13 4 CARDRAQGIVAAAGTSFGYW KT369792 3-25 (λ) 2 CQSGDTSGFDPDVAF 
HPK016_203 G (γ4) KT369793 5-51 2-15 4 CVRHCSGGRCSSAPLDSW KT369794 6-57 (λ) 3 CLSHDTTNFVF 
HPK018_1B6 A (α1) KT369795 1-46 2-8 3 CAYWGADGFDIW KT369796 1-44 (λ) 3 CAVWDDSLSAWVF 
HPK018_1F3 G (γ1) KT369797 1-69 3-9 4 CARGMTGYVGAYDYW KT369798 1-44 (λ) 3 CASWDDRLNGPVF 
HPK018_2D6 A (α1) KT369799 3-49 2-2 4 CTTYCSSTSCQIDYW KT369800 2-14 (λ) 1 CSSYTGSSGYVV 
